The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 68.50
Bid: 65.00
Ask: 72.00
Change: 6.00 (9.60%)
Spread: 7.00 (10.769%)
Open: 62.50
High: 68.50
Low: 62.50
Prev. Close: 62.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Feedback Medical to offer Bleepa for COVID-19

26 Mar 2020 15:52

RNS Number : 7614H
Feedback PLC
26 March 2020
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR").

 

Feedback plc

 

Feedback Medical to offer Bleepa to assist Coronavirus response

 

Feedback Medical and Pennine pilot study paused to evaluate a wider rollout to support the local COVID-19 response at the Pennine NHS Trust

Bleepa® enables medical staff to review imaging studies and discuss cases remotely while they or colleagues self-isolate during the Coronavirus outbreak

Bleepa® selected for the Top 100 UK Digital Health Firms by Healthcare UK at the Department for International Trade (DIT), and has been included in a catalogue 100 offerings being championed to the NHS by South East Health Technologies Alliance (SEHTA)

 

London, 26 March 2020: Feedback Medical Ltd, a wholly-owned subsidiary of Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that it will provide Bleepa®, Feedback's flagship imaging-based communication platform as a tool to assist coronavirus response.

 

Owing to the immense workforce pressures facing the clinical frontline at this time, Feedback and Pennine NHS Trust have elected to pause the Bleepa pilot, which was focusing on evaluating specific clinical workflow applications of Bleepa, and are now evaluating options for a wider rollout to support the local COVID-19 response at the Trust. It is hoped that this solution will subsequently be rolled out to other centres.

 

Tom Oakley, CEO of Feedback plc, said:

"The Coronavirus outbreak has created a unique and highly pressured situation for the NHS and other healthcare providers. At this time it is vital that clinicians who may be forced to self-isolate are provided with a tool that will allow them to continue supporting care delivery to colleagues who remain on the frontline. Imaging is such a core component of delivering effective care that any remote working solution will need to deliver access to quality images and there is no better tool to do this than Bleepa®."

 

The current Coronavirus outbreak has led to a significant increase in the volume of critical medical imaging studies, with chest X-rays and CT scans being key aids to diagnose and manage patients with Coronavirus. In addition to Radiologists, other frontline clinicians will take a central role in reviewing the growing Coronavirus caseload. As the outbreak develops these individuals will increasingly need to review cases from home and emergency and routine workflows will have to adapt as NHS staff themselves increasingly become home-based as self-isolation grows.

 

Home-based image review and case discussion at this scale requires a new infrastructure and a secure bespoke imaging solution which is capable of scaling to meet these demands. Bleepa® is designed for exactly this purpose and overcomes the problems associated with trying to scale traditional VPN-based remote access solutions to hospital software.

 

Bleepa® is a secure image-based communication platform which provides access to clinical grade medical images and facilitates instant messaging based case discussion through a zero footprint application. Bleepa® can be accessed from any internet connected device including phones, tablets, laptops and desktops; clinicians can use their own devices and therefore no additional hardware is required.

 

Any medical imaging investigation can be seamlessly shared through Bleepa® to the entire clinical team, even if those teams are geographically separated or having to work remotely. Cases can be discussed through secure instant messaging and image annotation, allowing comments and decisions to be communicated instantly between team members. Importantly, during the outbreak, Bleepa® can enable case review by clinicians at other hospitals where multisite communication is needed.

 

Bleepa is able to support care delivery in other healthcare systems internationally and in recognition of this Bleepa has been selected as one of the Top 100 UK Digital Health Firms by Healthcare UK at the Department for International Trade as part of their international offering of UK companies that could support with coronavirus response overseas. Bleepa has also been included in a brochure of 100 company offers compiled by the South East Health Technologies Alliance which is being shared with NHS Trusts as solutions that can help in the COVID-19 response. It is hoped that these offerings will help to highlight the ability of Bleepa to support healthcare providers both within the NHS and internationally. Insofar as it is possible, Feedback intends to offer Bleepa for free for the duration of the coronavirus outbreak.

 

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

 

+44 (0)1954 718072

IR@fbk.com

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

 

+44 (0)20 3328 5656

Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey

 

+44 (0)20 7469 0936

Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 20 3815 8880

 

 

Instinctif Partners

Melanie Toyne-Sewell / Phillip Marriage

 

+44 (0)20 7457 2020

feedbackplc@instinctif.com

 

Notes to editors 

 

About Feedback plc - www.fbk.com

 

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owne trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. 

 

Feedback has launched Bleepa, a new secure, encrypted medical communication app for clinicians accessible through smartphones, tablets and desktops that facilitates rapid clinical messaging and review of medical grade imaging for all members of a clinical team, directly from a hospital Picture Archiving and Communications System (PACS). For more information on Bleepa, see www.bleepa.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCDZGZFKVLGGZM
Date   Source Headline
30th Jun 20172:21 pmRNSHolding(s) in Company
30th Jun 201712:41 pmRNSIssue of Equity
8th Jun 20171:15 pmRNSCCI Exclusive Distributor Agreement with Korea ISG
8th Jun 20171:11 pmRNSDirectorate Change
1st Jun 20179:23 amRNSTotal Voting Rights
30th May 20174:38 pmRNSFurther re. Notice of Resignation of Director
18th May 20177:00 amRNSProgress with CE Mark and trading update
12th May 201711:57 amRNSHolding(s) in Company
2nd May 20177:00 amRNSNotice of Resignation of Director
26th Apr 20177:00 amRNSIssue of Equity
30th Mar 20177:00 amRNSLetter of Intent signed and trading update
3rd Mar 20177:00 amRNSAppointment of Joint Broker
20th Feb 20177:00 amRNSHalf-year Report
23rd Jan 20171:28 pmRNSRe: Media Articles
30th Nov 20165:00 pmRNSTotal Voting Rights
24th Nov 201612:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20161:20 pmRNSIssue of Equity & Director / PDMR Shareholding
23rd Nov 201610:33 amRNSResult of AGM
16th Nov 20167:00 amRNSAttendance at RSNA 2016
19th Oct 20163:17 pmRNSRe: Directorate
19th Oct 20167:00 amRNSFinal results for the year ended 31 May 2016
21st Sep 201612:30 pmRNSTrading Update
28th Jul 20161:31 pmRNSCollaboration with Future Processing
1st Jun 201612:30 pmRNSAppointment of Non-Executive Chairman
3rd May 201612:00 pmRNSDisposal
2nd Mar 20167:00 amRNSChange of Nominated Adviser
22nd Feb 20167:00 amRNSInterim Results for the 6 months ended 30 Nov 2015
30th Nov 20152:59 pmRNSResult of AGM
23rd Nov 20157:00 amRNSTexRAD Update
6th Nov 20157:01 amRNSDirectorate Change
6th Nov 20157:00 amRNSFinal Results
8th Oct 20157:00 amRNSStrategy Update
6th Oct 20159:45 amRNSNHS publication on potential application of TexRAD
5th Oct 20157:00 amRNSTexRAD Prostate Cancer Product Development
28th Sep 20157:00 amRNSLicence of TexRAD to Stone Checker
9th Sep 20157:00 amRNSFirst sale of TexRAD in China
31st Jul 20157:00 amRNSTotal Voting Rights
20th Jul 20157:00 amRNSStudy Results
9th Jul 20158:39 amRNSExercise of Options
6th Jul 20152:08 pmRNSIssue of Equity
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20157:00 amRNSFirst server sale of TexRAD in Canada
4th Jun 20159:56 amRNSStmnt re Share Price Movement
3rd Jun 20157:00 amRNSIssue of Equity
15th May 20157:00 amRNSCollaboration with University of Texas
11th May 20153:09 pmRNSPreliminary results from the Oxford Stone Group
29th Apr 20157:00 amRNSDrug Trial and Trading Update
28th Apr 20157:00 amRNSCollaboration with Princess Alexandra Hospital, AU
27th Apr 20157:00 amRNSFirst sale of TexRAD in South Korea
23rd Apr 201512:15 pmRNSStmnt re Share Price Movement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.